#Genvoya

Swiss researchers analyzed shifts in kidney function among those switching from the old form of the HIV medication to the new one.

Currently, Gilead Sciences’ HIV regimen is not approved to treat drug-resistant virus.

That’s according to a study of 55 HIV-positive people with end-stage kidney failure.

Gilead has based its entire HIV drug portfolio on updating tenofovir, ostensibly to make it safer for bones and kidneys.

Researchers call for closer cardiovascular monitoring for those switching from the TDF form of the drug to the TAF version.

This is according to a French study looking at discontinuations of Tivicay compared with Vitekta and Isentress.

That’s compared with HIV-negative men.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

The AIDS Healthcare Foundation alleges Gilead could have developed the safer version of tenofovir earlier.

Increases may be designed to push patients to the company’s newer regimens.

The pharma giant knew about the safer HIV med but allegedly stopped research in order to extend its patent profits.

The FDA has approved Gilead Science’s Genvoya, which is the first HIV treatment to include an updated version of tenofovir.

The FDA has approved Gilead’s single-tablet antiretroviral regimen Genvoya, the first HIV treatment to include a new version of tenofovir.